Life Sciences Tools and Services
Company Overview of Aegis Therapeutics, LLC
Aegis Therapeutics, LLC, a drug-delivery and drug-formulation technologies company, commercializes drug delivery and protein stabilization technologies to pharmaceutical and biopharmaceutical companies. It offers Intravail, a drug delivery technology that enables the non-invasive delivery of a broad range of protein, peptide, and non-peptide drugs. The company also provides ProTek to create homogeneous, stable, aqueous or lyophilized dosage forms for peptide or protein therapeutics. In addition, it offers Hydrogels, an absorption-enhancing self-assembling aqueous hydrogels for transdermal drug delivery or transmucosal application. The company was founded in 2003 and is based in San Diego, Ca...
11770 Bernardo Plaza Court
San Diego, CA 92128
Founded in 2003
Key Executives for Aegis Therapeutics, LLC
Chief Executive Officer and Director
Chief Business Officer and Director
Compensation as of Fiscal Year 2014.
Aegis Therapeutics, LLC Key Developments
Aegis Offers Exclusive License to Develop, Commercialize, and Sell its Patented Non-Invasive Exenatide Metered Nasal Spray Diabetes Drug
Aug 5 14
Aegis announced that it is offering an exclusive license to develop, commercialize, and sell its patented non-invasive exenatide metered nasal spray diabetes drug. Exenatide is a 39-amino acid synthetic peptide GLP-1 analog highly effective in controlling blood glucose levels in Type-2 diabetes. All currently available GLP-1 analogs require injection. The currently marketed injectable form of exenatide, sold under the trademark Byetta(R), requires twice daily injections. The Aegis patented Intravail(R) based formulation of exenatide provides equivalent blood levels using a simple metered nasal spray to replace each of the two daily injections. The total market for GLP-1 analogs is expected to grow to $5 billion within the next few years. As the only non-injectable option for patients seeking to avoid needles, needlestick injuries, and syringe disposal problems, the non-injectable Aegis nasal spray exenatide formulation is poised to achieve significant market share.
Aegis Therapeutics, LLC Presents at BIO International Convention, Jun-25-2014 04:15 PM
Jun 17 14
Aegis Therapeutics, LLC Presents at BIO International Convention, Jun-25-2014 04:15 PM. Venue: San Diego Convention Center, San Diego, California, United States.
Aegis Intravail(R) Technology Enhances Oral Bioavailability of Tableted OTC Drugs
Mar 12 14
Aegis Therapeutics LLC's Intravail(R) technology has been successfully formulated with phenylephrine in compressed tablets, dramatically improving oral bioavailability by more than 50%. This is the first application of Intravail(R) in a solid dosage form. The Intravail formulation is compatible with current tableting processes employed for OTC and prescription drugs and does not alter tablet size or appearance. Previously published studies have shown that Intravail(R) alkylsaccharide excipients increase oral bioavailability of a number of peptide and nonpeptide drugs in preclinical studies. Examples include exenatide, octreotide, desmopressin, heparin, sumatriptan and a 7kDa antisense (nucleotide analog) drug. In these latter applications, Intravail was incorporated into aqueous formulations or fast dissolve or chewable formats. The extension of the use of Intravail(R) into solid dosage forms represents a significant expansion of the broad applicability of this technology. Intravail(R) excipients are equally soluble in pharmaceutically accepted oils thus permitting use as oral absorption enhancers in gel caps as well. Sixteen US and foreign patents have issued to date and Notice of Allowance has been received on two additional patents that will issue shortly covering various aspects of the Intravail(R)/ProTek(R) alkylsaccharide-based technologies. More than 50 additional patent applications are currently pending. Aegis licenses its Intravail(R) drug delivery and ProTek(R) protein stabilization technologies to biopharmaceutical companies worldwide and is now seeking licensees for the application of Intravail to a broad range of over-the-counter drugs where increased bioavailability or more rapid onset of action would offer improved performance and significant market differentiation in a crowded field.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|